A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Status:
Recruiting
Trial end date:
2026-12-15
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant
treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet
chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell
lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.